Skip to main content

Vericel Value Stock - Dividend - Research Selection

Vericel

ISIN: US92346J1088, WKN: A12FU4

Market price date: 02.06.2021
Market price: 55,46 USD




Vericel Fundamental data and company key figures of the share

Annual reports in USD
Key figures 02-03-2021
Cash flow
Net operating cash flow 17.572.000
Capital Expenditures -2.626.000
Free cash flow 14.946.000
Balance sheet
Total Equity 134.260.000
Liabilities & Shareholders equity 205.608.000
Income statement
Net income 2.864.000
Eps (diluted) 0,060
Diluted shares outstanding 45.804.000
Net sales/revenue 124.179.000

Fundamental ratios calculated on: 02-06-2021

Ratios
Key figures 02-06-2021
Cash flow
P/C 144,57
   
P/FC 169,97
Balance sheet
ROI1,39
ROE65,30
Income statement
P/E924,33
Div. Yield0,00%
P/B18,92
P/S20,46


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolVCEL
Market Capitalization2.540.289.792,00 USD
Country
IndicesNASDAQ Comp.
Sectors
Raw Data SourceUS GAAP in Millionen USD
Stock Split2013-10-16,1.0000/20.0000; 2010-02-18,1.0000/8.0000
Internetwww.vcel.com


Description of the company

Vericel Corporation, formerly Aastrom Biosciences, Inc., is a commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases segment. Its autologous cell therapy products include Carticel (autologous cultured chondrocytes), which is an autologous chondrocyte implant for the treatment of cartilage defects in the knee, and Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.vcel.com